GSK PLC Sponsored ADR $GSK Stock Holdings Lifted by Miller Howard Investments Inc. NY

Key Points

• Miller Howard Investments Inc. increased its stake in GSK PLC by 0.8%, acquiring over 13,000 additional shares during the second quarter, representing 2.0% of its total holdings.
• GSK recently reported earnings of $1.23 per share, exceeding analysts' estimates, with quarterly revenues of $10.64 billion, up 1.3% from the previous year.
• GSK announced a quarterly dividend of $0.4206, reflecting an annualized dividend yield of 4.1% despite a payout ratio of 77.78%.

Miller Howard Investments Inc. NY lifted its position in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 0.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,659,814 shares of the pharmaceutical company's stock after acquiring an additional 13,023 shares during the period. GSK comprises approximately 2.0% of Miller Howard Investments Inc. NY's holdings, making the stock its 15th largest position. Miller Howard Investments Inc. NY owned approximately 0.08% of GSK worth $63,737,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GSK. Brighton Jones LLC purchased a new position in GSK during the 4th quarter worth approximately $528,000. Tidal Investments LLC grew its holdings in shares of GSK by 6.2% during the fourth quarter. Tidal Investments LLC now owns 31,015 shares of the pharmaceutical company's stock valued at $1,049,000 after buying an additional 1,823 shares in the last quarter. Two Sigma Investments LP grew its holdings in shares of GSK by 602.5% during the fourth quarter. Two Sigma Investments LP now owns 574,754 shares of the pharmaceutical company's stock valued at $19,438,000 after buying an additional 492,934 shares in the last quarter. Vident Advisory LLC grew its holdings in shares of GSK by 4.2% during the fourth quarter. Vident Advisory LLC now owns 20,080 shares of the pharmaceutical company's stock valued at $679,000 after buying an additional 813 shares in the last quarter. Finally, Waverly Advisors LLC grew its stake in GSK by 113.2% during the 4th quarter. Waverly Advisors LLC now owns 13,233 shares of the pharmaceutical company's stock valued at $448,000 after acquiring an additional 7,025 shares in the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Stock Up 0.8%

Shares of GSK stock opened at $40.63 on Friday. The stock has a market cap of $82.75 billion, a P/E ratio of 18.81, a price-to-earnings-growth ratio of 2.01 and a beta of 0.53. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.87 and a quick ratio of 0.57. GSK PLC Sponsored ADR has a one year low of $31.72 and a one year high of $42.63. The stock has a fifty day moving average price of $38.90 and a 200 day moving average price of $38.55.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, topping analysts' consensus estimates of $1.12 by $0.11. The firm had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $7.92 billion. GSK had a net margin of 10.81% and a return on equity of 49.22%. The company's revenue for the quarter was up 1.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.43 earnings per share. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Analysts predict that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be paid a $0.4206 dividend. The ex-dividend date is Friday, August 15th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 4.1%. GSK's payout ratio is 77.78%.

Wall Street Analyst Weigh In

GSK has been the topic of a number of research analyst reports. Wall Street Zen raised shares of GSK from a "buy" rating to a "strong-buy" rating in a research report on Friday, September 5th. Berenberg Bank restated a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Six analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Reduce" and an average price target of $37.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK PLC Sponsored ADR (NYSE:GSK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.